Elanco Scales Biologics Capabilities With Expansion of Kansas Manufacturing Facility
Elanco completed a 25,000-square-foot expansion of its Elwood, Kansas facility, part of a total $150 million investment to quadruple monoclonal antibody production capacity. The expansion addresses strong demand for recently launched products Befrena and Trutect, with customer demand for Befrena currently running at twice initial expectations.
Key figures
- Expansion sqft
- 25000
- Survey respondents
- 1409
- Capacity increase multiplier
- more than four times
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.